

Heparan sulfate dependent phase separation of CCL5 and its chemotactic activity

Reviewed Preprint

Published from the original preprint after peer review and assessment by eLife.

About eLife's process

Reviewed preprint version 1

March 4, 2024 (this version)

Posted to preprint server

November 16, 2023

Sent for peer review

November 9, 2023

Xiaolin Yu, Guangfei Duan, Pengfei Pei, Long Chen, Renji Gu, Wenrui Hu, Hongli Zhang, Yan-Dong Wang, Lili Gong, Lihong Liu, Ting-Ting Chu , Jin-Ping Li , Shi-Zhong Luo 

Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China • Institute of Medical Science, China-Japan Friendship Hospital, Beijing, 100029, China • Greater Bay Biomedical InnoCenter, Shenzhen Bay Laboratory, Shenzhen, China • Beijing Advanced Innovation Centre for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, China • Department of Medical Biochemistry and Microbiology, University of Uppsala, Uppsala, Sweden

 https://en.wikipedia.org/wiki/Open_access

 Copyright information

Abstract

Secreted chemokines form concentration gradients in target tissues to control migratory directions and patterns of immune cells in response to inflammatory stimulation; however, how the gradients are formed is much debated. Heparan sulfate (HS) binds to chemokines and modulates their activities. In this study, we investigated the roles of HS in the gradient formation and chemoattractant activity of CCL5 that is known to bind to HS. CCL5 and heparin underwent liquid–liquid phase separation (LLPS) and formed gradient, which was confirmed using CCL5 immobilized on heparin-beads. The biological implication of HS in CCL5 gradient formation was established in CHO-K1 (wild type) and CHO-677 (lacking HS) cells by Transwell assay. The effect of HS on CCL5 chemoattractant activity was further proved by transwell assay of human peripheral blood cells. Finally, peritoneal injection of the chemokine into mice showed reduced recruitment of inflammatory cells either by mutant CCL5 (lacking heparin binding sequence) or by addition of heparin to wild type CCL5. Our experimental data propose that co-phase separation of CCL5 with HS establishes a specific chemokine concentration gradient to trigger directional cell migration. The results warrant further investigation on other heparin binding chemokines and allows for a more elaborate insight into disease process and new treatment strategies.

eLife assessment

How the triplicate interaction between chemokines with both GAGs and G protein-coupled receptors (GPCR) works and how gradients are created and potentially maintained in vivo are poorly understood. The authors provide **solid** evidence to show phase separation can drive chemotactic gradient formation. The paper is a **useful** advance in the field of chemokine biology.

Introduction

Gradients of signaling molecules are ubiquitous in embryonic development and cellular activities, modulating cell migration, proliferation, and survival (Griffith, Sokol et al., 2014 [↗](#), Yamamoto, Kambayashi et al., 2022 [↗](#), Yu, Burkhardt et al., 2009 [↗](#)). Chemokines, belonging to a ~45-member family of small (8-12 kDa) proteins, are signaling molecules that can induce distinct cellular chemotaxis in response to inflammatory stimuli in a concentration-dependent gradient (Weber, Hauschild et al., 2013). Chemokines play critical roles in regulating cell migration in a wide range of biological activities, e.g. developmental, homeostatic and inflammatory/pathological processes (Douglas, Dyer et al., 2015 [↗](#)). It is established that chemokines are secreted from source cells and immobilized on glycosaminoglycans (GAGs) including heparan sulfate (HS) in the extracellular matrix (Proudfoot, Handel et al., 2003 [↗](#)). The interaction of GAG-chemokine forms an immobilized gradient to provide direction to cell movement (Proudfoot, Johnson et al., 2017 [↗](#)). Understanding how these chemokine gradients are formed and maintained is fundamental to identifying how they direct cell migration and proliferation. Straightforward molecular diffusion is often proposed as a possible mechanism (Kicheva, Pantazis et al., 2007 [↗](#), Schier & Needleman, 2009 [↗](#), Yu et al., 2009 [↗](#)). However, it is assumed that more complicated mechanisms are involved, which remains to be elucidated.

CCL5 (also known as RANTES, for ‘regulated on activation normal T cell expressed and secreted’) (Rosic-Mrkic, Fischer et al., 2003 [↗](#)) is an inflammatory chemokine that recruits a wide variety of leukocytes, including monocytes, granulocytes, and T cells, as well as mast cells and dendritic cells, through chemokine gradients (Roy, Mondal et al., 2015 [↗](#), Weber et al., 2013 [↗](#)). CCL5 is composed 68 amino acids that reversibly self-assembles into high-MW oligomers, up to >600 kDa. This highly basic protein binds heparin with high affinity (Mulloy, 2005 [↗](#)) and the oligomerization of CCL5 for the formation of gradient is modulated by GAGs on cell surface (Proudfoot et al., 2003 [↗](#)).

Liquid–liquid phase separation (LLPS) driven by weak interactions between multivalent biomolecules was shown to be an important mechanism by which mesoscale structures of the condensates can form within the cell (Xue, Gong et al., 2019 [↗](#)) and on the cell surface (Xue, Zhou et al., 2022 [↗](#)). Within phase-separated condensates, biomolecules are often mobile and interchanged between the dense and light phases. Based on reported information and our previous study, we have studied the implications of HS on CCL5 gradient formation and its chemotactic activity. Both in vitro and in vivo experiments demonstrate that co-phase separation of CCL5 with HS establishes specific chemokine concentration gradients for chemotactic activity.

Results

Co-phase separation of CCL5 and heparin

To illustrate the phase separation property of CCL5 in liquid, recombinant protein expressed in *E. coli* (**Figure 1—figure supplement 1A** [↗](#)) (Proudfoot, Power et al., 1996 [↗](#)) was labeled with organic dye Cy3 and mixed with heparin at different ratios. After 30 min formation of droplets was examined by fluorescence under confocal microscopy. At the ratio of 20:1 CCL5 to heparin, few tiny droplets were detected, indicating phase separation. With increased ratio of CCL5: heparin to 1:20, large and round droplets were formed (**Figure 1A and B** [↗](#)). Further increases in heparin concentration (ratio 1:50) prevented droplet formation as a “reentrant” behavior. Since heparin is a linear repetitive structure with rich negative charges, the LLPS seems following a similar mechanism as RNA in the phase separation of many RNA binding proteins (Ghosh, Mazarakos et al., 2019 [↗](#)). Longer incubation revealed that the droplets were dynamic and some

became fused to form larger droplets (**Figure 1C**) that displayed a quick recovery speed in the fluorescence recovery after photobleaching (FRAP) (**Figure 1D**). The heparin-induced phase separation of CCL5 was attenuated at high salt concentrations as illustrated by incubation at different KCl concentrations in KMEI buffer (**Figure 1—figure supplement 2A and B**). In comparison, a mutant (A22K-CCL5) with higher positive charge density showed stronger interaction with heparin (Brandner, Rek et al., 2009) and was able to form aggregates with heparin in KMEI buffer (**Figure 1—figure supplement 2C and D**). These results indicated that heparin-induced LLPS of CCL5 was based on weak electrostatic interactions between the negatively charged polysaccharide and the basic protein of CCL5.

To further confirm this hypothesis, we mutated ⁴⁴RKNR⁴⁷, a conserved positively charged BBXB motif of CCL5, to hydrophobic alanine motif ⁴⁴AANA⁴⁷ (Proudfoot, Fritchley et al., 2001), which is expected to reduce the interaction with heparin. As anticipated, the phase separation of the mutant ⁴⁴AANA⁴⁷-CCL5 in solution containing heparin formed much smaller droplets in comparison to WT CCL5 (**Figure 1E, F**). The electrostatic interaction feature was further demonstrated by molecular docking analysis using a tetrasaccharide structure of heparin (**Figure 1—figure supplement 3A**). The results showed the docking of heparin tetrasaccharide into human CCL5, forming crucial electrostatic contacts at the CCL5 dimer interface, where it packed tightly against Arg 44, Lys45, Arg47. (**Figure 1—figure supplement 3A**). In comparison, binding free energy of heparin to the ⁴⁴AANA⁴⁷-CCL5 mutant was significantly higher (**Figure 1—figure supplement 3B**).

Heparin dependent phase separation is one essential step for CCL5 gradient formation

To elucidate the intrinsic connection between the heparin-dependent phase separation of CCL5 and its chemotactic activity, we developed an in vitro diffusion assay in which purified His-CCL5-EGFP (**Figure 1—figure supplement 1B**) was immobilized on heparin-beads or on Ni-NTA-beads. In 96-well plates, the beads were embedded in the center of Matrigel (Helen P. Makarenkova, 2009) and incubated for 12 hr. Diffusion of the CCL5-EGFP was monitored by measuring fluorescence intensity along a line interval passing through the bead localized center. As shown in **Figure 2A**, CCL5-EGFP diffused a considerable distance away from the heparin-beads, forming a long and shallow gradient, whereas CCL5-EGFP did not diffuse from the Ni-NTA beads (**Figure 2B**). In comparison, ⁴⁴AANA⁴⁷-CCL5 binding to the heparin-beads was significantly weaker and did not diffuse (**Figure 2A**, right panel). To exclude the potential effect of EGFP, we repeated the experiment using Cy3-tagged CCL5. In a similar manner, the heparin-beads bound Cy3-CCL5 diffused in Matrigel but not the Ni-NTA beads bound Cy3-CCL5 as revealed by 3D imaging (**Figure 2—figure supplement 1** and **Figure 2—figure supplement 2**). These results suggest that heparin beads tethered CCL5 via phase separation, which enables rapid exchange with the external environment leading to diffusion and gradient formation; while the Ni-NTA beads bound CCL5 lacks phase separation, therefore no diffusion.

Next, to test whether the formed chemokine gradients of CCL5-heparin beads contribute to the chemotactic activity, we established an in vitro chemotaxis assay using Transwell (Proudfoot et al., 2003) in which CCL5 either in heparin-beads or in Ni-beads were placed in the lower chamber (**Figure 2C**) and THP-1 cells were placed in the upper chamber. Again, CCL5-heparin-beads showed robustly higher chemotactic activity (**Figure 2D**), while CCL5-Ni-NTA beads essentially did not induce chemotaxis. In comparison, ⁴⁴AANA⁴⁷-CCL5-heparin-beads showed relatively weaker chemotactic activity than WT-CCL5-heparin-beads (**Figure 2D**). The dramatic difference in the chemotactic activity of CCL5 between immobilization on heparin-beads or Ni-NTA beads indicate that the chemotactic function is achieved by establishment of a functional gradient rather than just immobilization.




Figure 1

CCL5 phase separates with heparin in solution.

(A) Confocal images of assembling status of 20 μ M CCL5-Cy3 mixed with heparin at different ratios and 5% PEG. Scale bar=10 μ m. (B) Turbidity changes with increase of heparin concentration were measured at 620 nm. (C) Fusion of phase-separated droplets formed at the ratio of CCL5-Cy3: heparin=1:2. The white arrows indicate the dynamic fusion of two adjacent droplets. (D) Representative FRAP results of droplets formed by CCL5-Cy3: heparin=1:2 depicted in [Figure 1A](#), showing the intensity of fluorescence pre- and after photobleaching. The images of representative droplets in different recovery stages are shown. (E) Confocal images of assembling status of ⁴⁴AANA⁴⁷-CCL5 or CCL5 in the presence of heparin. Scale bar=10 μ m. (F) Comparison of CCL5 and ⁴⁴AANA⁴⁷-CCL5 turbidity in the presence of heparin. Data are mean $\pm$ s.d. n=3 (for B, F). *P* values were determined by unpaired two-tailed t-tests.




Figure 2

Co-phase separation of CCL5 and heparin establishes chemokine gradient

(A) CCL5-EGFP or $^{44}\text{AANA}^{47}\text{-CCL5-EGFP}$ were bound to heparin beads or Ni-NTA beads, respectively, and were placed in Matrigel in 96-well plate. After incubation for 12 hr images were taken to quantify the fluorescence intensity. (B) Quantification of the fluorescence signals along the lines with arrows indicated in **Figure 2A**. (C) Illustration of *in vitro* chemotaxis assay. (D) Heparin beads or Ni-NTA beads bound with CCL5 or $^{44}\text{AANA}^{47}\text{-CCL5}$ were placed in the lower chamber. THP-1 cells (3×10^5 cells) were added to upper chamber. After 5 hr, THP-1 in the lower chamber was collected and counted. Data are mean $\pm$ s.d. $n=3$. P values were determined by unpaired two-tailed t-tests.

Heparan sulfate dependent CCL5 phase separation and its chemotactic activity

Having seen the functional roles of heparin in CCL5 gradient formation in solution and Matrigel, we wanted to find out whether heparan sulfate (HS) on the cell surface also can phase separate with CCL5 using a pair of well-established cell line, CHO-K1 (wild type) and CHO-677 (mutant lacking HS). Co-incubation of CCL5-Cy3 with the cells resulted in strong signals on the cell surface of CHO-K1 revealed by confocal microscopy, indicating formation of puncta surrounding the cells (**Figure 3A**). However, CHO-677 completely lacked the signals. The finding was further verified by Z-stack scanning (**Figure 3B**). Fluorescence recovery of about 40% condensates after photobleaching (FRAP) indicates there is a liquidity of the condensates on CHO-K1 (**Figure 3C**). These results indicated that CCL5 formed phase separation with HS on the CHO K1 cell surface, which was not possible in CHO-677 cells lacking HS.

In order to know whether the HS-dependent CCL5 phase separation is essential for the chemotactic activity of CCL5, we established a cell-based chemotaxis assay (**Figure 3D**). CHO-K1 cells along with CCL5 was placed in the lower chamber and THP-1 cells was seeded in the upper chamber, separated by a porous membrane. After incubation for 5 hr, THP-1 cells transmigrated into the lower chamber was quantified. The results revealed that both CCL5 alone and CHO-K1 alone had low chemotactic activity; in contrast, CHO-K1 in the presence of CCL5 showed significantly higher chemotactic activity (**Figure 3E**). In the same line, the chemotactic activity of CCL5 was much lower when incubated with CHO-677 in the lower chamber. As it was found that higher proportion of heparin reduced phase separation of CCL5 (**Figure 1A**), we tested whether this is the case in cells. Indeed, addition of heparin in the incubation of CHO K1 abolished the phase separation of CCL5-Cy3 on the cells surface (**Figure 3A**, lower panel), accordingly attenuated the chemotactic activity of CCL5 (**Figure 3E**). When ⁴⁴AANA⁴⁷-CCL5 was incubated with CHO-K1 cell, no obvious phase-separated condensates appeared on the cell surface (**Figure 3—figure supplement 1**), and consequently, ⁴⁴AANA⁴⁷-CCL5 showed reduced chemotactic activity when incubated with CHO-K1 (**Figure 3E**) in comparison with WT CCL5. Thus, we may conclude that HS is essential on the CHO cell surface for phase separation of CCL5 and its chemotaxis function.

Based on the observation that CCL5 forms a concentration gradient on heparin-beads where heparin-driven phase separation enabled CCL5 diffuse, we hypothesized a similar scenario of HS on cells, e.g., CCL5 was immobilized or condensed by HS on the cell surface through phase separation, and gradually diffuse to form a gradient to guide cell migration. To test this conjecture, we transfected the construct of CCL5-EGFP into CHO-K1. The cells were co-cultured with Human Umbilical Vein Endothelial Cells (HUVEC) (Ynebrten, Barois et al., 2015). Released CCL5-EGFP from CHO-K1 cells was readily taken up by nearby HUVEC cells, formed bright phase-separated condensates on the cell surface (**Figure 4A** and **Figure 4—figure supplement 1A**). With extended incubation, the condensates became fused (**Figure 4B**), in a similar way of CCL5-heparin condensates in solution (**Figure 1C**). The FRAP experiment showed reasonable fluorescence recovery after photobleaching, indicating liquid-like properties of the condensates on the cell surface (**Figure 4C**). To further illustrate the gradient formation of the CCL5-EGFP condensates, we cultured HUVEC in Matrigel and embedded tiny amounts of the CCL5-EGFP transfected CHO-K1 as a source of CCL5-EGFP. Confocal microscopy monitoring found decreased concentration of CCL5-EGFP with increasing distance of HUVEC from the source cells (CCL5-EGFP expressing CHO), confirming that CCL5-EGFP established a gradient by phase separation on its target cells (**Figure 4D and E**, **Figure 4—figure supplement 1B and C**). Further, both CHO-K1 and CHO-677 transfected with CCL5-EGFP were analyzed on the same setting. The results show that a gradient was formed in CHO-K1 cells when co-cultured with CCL5-EGFP transfected CHO-K1 in Matrigel, while CHO-677 failed to form the concentration gradient (**Figure 4—figure supplement 1D**). Furthermore, the chemotactic activity was demonstrated by placing CCL5-




Figure. 3

CCL5 phase separates with heparan sulfate on the cell surface

(A) Microscopy images of CCL5-Cy3 on the surface CHO-K1 and 677 as well as CHO-K1 treated with 1 mg/mL heparin. From left to right, the images are fluorescent-field, bright-field and overlay of two illuminations. Scale bar=10 μ m. (B) Z-stack scanning of CCL5-Cy3 phase separation on CHO-K1 cell surface. The cell was imaged by confocal microscope with the Z-stack method. Scale bar=10 μ m. (C) FRAP of the condensates formed by CCL5-Cy3, showing the intensity of fluorescence pre- and after photobleaching. The size of the representative droplets in different recovery stages are shown above of the graph. (D) Graphical illustration of the cell-based chemotaxis assay. CHO cells (1×10^5 cells/well) were plated onto the lower chamber for 24 h (fully attached) and CCL5 or 44 AANA- 47 -CCL5 or heparin were added as indicated. THP-1 cells (3×10^5) were placed on upper chambers. After 5 h, a small volume of medium in the lower chamber was aspirated to count THP-1 transmigrated through the membrane. (E) Quantification of THP-1 collected from the lower chamber. Data are mean $\pm$ s.d. $n=3$. P values were determined by unpaired two-tailed t-tests.

EGFP transfected CHO-K1 in a lower chamber and THP-1 in the upper chamber. Counting the transmigrated THP-1 cells showed that the transfected CHO-K1 had stronger chemotactic activity compared with WT-CHO-K1([Figure 4F](#) [↗](#)).

Ex vivo and in vivo demonstration of HS-dependent chemotactic activity of CCL5

To further verify our findings, we placed HUVEC or CHO cells in the lower chamber in the presence of CCL5 and human peripheral cell (PBMC) in the upper chamber of the Transwell device to detect transmigration of PBMC. Quantification of the transmigrated cells into the lower chamber after incubation for 5 hr revealed that neither CCL5 alone nor CHO-677 in the presence of CCL5 showed substantial chemotactic activity; in contrast, HUVEC and CHO-K1 in the presence of CCL5 showed significantly higher chemotactic activity. It should be pointed out that the variation of total PBMC in the 3 blood samples varied dramatically, resulting in the great variations in the number of transmigrated cells of each sample. Nevertheless, the trend of chemotactic activity under different conditions is consistent in all samples ([Figure 5](#) [↗](#)).

To verify our findings in vivo, wild-type or mutant CCL5 was injected into the peritoneal cavity of Balb/c mice and peritoneal cells recruitment was monitored([Proudfoot et al., 2003](#) [↗](#)). Wild-type CCL5 induced a robust increase of total cells in the peritoneal lavage to a level approximately 4-fold over the saline control ([Figure 6](#) [↗](#)). In comparison, though ⁴⁴AANA⁴⁷-CCL5 group had a higher cell number than saline control, the recruited cells was much less than CCL5. Heparin (1 mg/mL) co-injected with wild-type CCL5 attenuated the recruitment of inflammatory cells, which, again, can be ascribed to the competitive interaction with endogenous HS in binding to CCL5. Overall, these results demonstrate that the phase separation of CCL5 with HS indeed contribute to chemotaxis function of CCL5 in vivo.

Discussion

This result may represent an in vivo scenario that more chemokines are released under inflammatory conditions, leading to a stronger chemotactic activity. It has been suggested that an important component of the chemokine-signaling is formation of a haptotactic gradient through immobilization of chemokines on cell surface glycosaminoglycans (GAGs)([Helen P. Makarenkova, 2009](#) [↗](#)). Interactions with GAGs facilitate gradient formation of chemokine, providing directional cues for migrating cells. Heparan sulfate (HS) is one member of the GAGs family and ubiquitously expressed on the cells surface of endothelial and epithelial cells, forming glycocalyx([Simon Davis & Parish, 2013](#) [↗](#)). It is known that HS (and its analogue heparin) binds to a broad spectrum of cytokines, functioning as a co-receptor to mediate signaling activity of the cytokines([Xie & Li, 2019](#) [↗](#)). Several inflammatory chemokines, including CCL5, binds to HS/heparin([Proudfoot et al., 2003](#) [↗](#)); however, the molecular mechanisms of HS in CCL5 - induced chemotactic activity has not been reported.

Phase separation is a common mechanism for protein assembly and compartmentalization, and it contributes to a variety of cellular processes, including the formation of membraneless organelles, signaling complexes, the cytoskeleton and numerous other supramolecular assemblies([Hyman, Weber et al., 2014](#) [↗](#), [Zbinden, Pérez-Berlanga et al., 2020](#) [↗](#)). Emerging evidence indicates that biomolecules in phase-separated liquid droplets are mobile and transiently interact with surrounding molecules([Nakashima, Vibhute et al., 2019](#) [↗](#)). CC chemokines are found to occur oligomerization in vivo, which may be modulated by GAGs([Hoogewerf, Kuschert et al., 1997](#) [↗](#)). Indeed, a conserved and positively charged BBXB motif in the CC chemokines is the key to interact with negatively charged GAGs through multivalent weak ionic interactions([Liang, Wenguang et al.,](#)




Figure 4

Formation of chemokine gradient on the cell surface by phase separation

(A) HUVEC cells were seeded on the plates for 24 h and stained with Dil (red). After washing with PBS, CCL5-EGFP transfected CHO-K1 were added and co-cultured for 24 hr before taking the images (Scale bar=10 μm). (B) Fusion events of droplets formed by CCL5-EGFP on HUVEC cell surface. The white arrows in cropped images indicate the fusion of two droplets with time. (C) FRAP of the condensates formed by CCL5-EGFP in HUVEC cell surface, showing the intensity of fluorescence pre and after photobleaching. The images of representative droplets in different recovery stages are shown. (D) HUVEC cells were seeded on the plate and firmly adhered before adding the CCL5-EGFP transfected CHO-K1 placed in 50% of Matrigel. After 1 hr co-culture, confocal images were taken showing CCL5-EGFP diffusion on the surface of HUVEC. Dotted white circle indicates the source cell of CCL5-EGFP transfected CHO-K1. Scale bar=100 μm . (E) Quantification of the fluorescence intensity shows decreased signals of CCL5-EGFP as the distance from the source cells increased. (F) The chemotaxis assay (same experimental conditions as described in [Figure 1](#)) shows higher activity of CCL5-EGFP transfected CHO-K1 cells than wild type CHO-K1 cells. Data are mean $\pm$ s.d. $n=3$. P values were determined by unpaired two-tailed t-tests.




Figure 5

Transmigration of human peripheral blood cells

The cells (CHO-K1, CHO-677, or HUVEC) (1×10^5 cells/well) as indicated were plated onto the lower chamber for 24 h (fully attached) and CCL5 was added. PBMC isolated from three healthy volunteer donors were placed in the upper chamber (total number of cells: Sample 1: 8.65×10^5 ; Sample 2: 2.31×10^6 ; Sample 3: 2.23×10^6). After culturing for 5 hr, the total transmigrated cells in the lower chamber were counted.




Figure 6

Chemokines phase separation promotes cell recruitment in vivo.

Mice were treated by intraperitoneal injection of CCL5 or the reagents as indicated. After 18h, the animals were sacrificed and peritoneal lavage was collected. Total cell number was counted by automated cell counter. Data are mean $\pm$ s.d. $n=4$. P values were determined by unpaired two-tailed t-tests.

2016 [\[1\]](#)). Between the CCL5 dimers, Structural study revealed that the basic amino acids R44, K45, and R47 create two positively charged regions on the interface of dimer and interact with heparin (Lortat-Jacob, Grosdidier et al., 2002 [\[2\]](#)).

Using our established liquid-liquid phase separation (LLPS) method, we demonstrated that CCL5 phases separate on the cell surface via a heparan sulfate (HS) dependent mechanism, which is required for CCL5 chemotaxis. Mutations on the basic amino acids R44, K45, and R47 resulted in losing binding of CCL5 to heparin beads, accordingly, lost its chemotactic activity. This finding also supports the fact that the phase separation of CCL5 with HS is mediated by weak electrostatic interactions, which facilitates the diffusion of CCL5 in solution to form gradient.

It is well established that HS constitutes the major component of glycocalyx on the endothelial cell surface (Oshima, King et al., 2021 [\[3\]](#)), and our earlier results showed that degradation of endothelial surface HS by heparanase impaired the function of MIP-2/CXCL2 induced leukocyte rolling, adhesion and transmigration (Massena, Christoffersson et al., 2010 [\[4\]](#)). From the finding of this study that the ratio of CCL5: heparin modulated droplets and condensates formation (**Figure 1A and B** [\[5\]](#)), we may assume that HS on the cell surface should have a sufficient capacity to interact with chemokines, controlling their chemotactic activity and inflammatory cell migration. This assumption is supported by the finding that overexpressing CCL5 in CHO-K1 cells led to higher chemotactic activity, which may represent a scenario of acute inflammatory reaction.

Collectively, our studies provide the first evidence that CCL5 gradient formation and chemotactic activity are dependent on HS. The interaction between CCL5 and HS is through a weak multivalent electrostatic binding, which facilitates LLPS and diffusion of the chemokine (**Figure 7** [\[6\]](#)). Notably, the results suggest that there may exist a physiological balance between CCL5 and HS, modulating the chemokine activity. This finding supports the hypothesis to develop chemokine-binding HS-mimetics that may competitively interfere with the HS-chemokine binding and phase separation, accordingly modulating inflammatory reactions.

Materials and Methods

Protein expression and purification

DNA sequences of wildtype human CCL5 were synthesized by General Biosystems, China. For the mutant of CCL5 (⁴⁴AANA⁴⁷-CCL5), site-directed mutations were introduced using the Quikchange mutagenesis kit (Beyotime Biotechnology, China) using mutagenesis primes: 5'-GCAGTCGTCTTTGTACCGCGCGAACGCGCAAGTGTGTGCCAACCCA-3'. CCL5 gene and ⁴⁴AANA⁴⁷-CCL5 gene were constructed in pET-28a vector (Miao Ling Plasmid, China) and transformed into *E. coli* Rosetta (DE3), (Biomed, China) for expression (Proudfoot et al., 1996 [\[7\]](#), Proudfoot & Borlat, 2000 [\[8\]](#)). The products contained an additional Met residue at the N-terminus (Met-CCL5) and His tag or EGFP-fusion protein. Bacterium were grown to optical density of 0.6 at 37 °C and induced with 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at 37 °C for 5 h. The cells were harvested by centrifugation (4000 rpm, 20 min at 4 °C), resuspended in lysis buffer (25 mM Tris-HCl, 100 mM NaCl, pH 8.0) and disrupted by sonication. The cell lysate was centrifuged at 12000 rpm for 35 min at 4 °C. To recover the recombinant CCL5 and ⁴⁴AANA⁴⁷-CCL5 proteins that were mainly distributed in the inclusion bodies, the pellet was collected and resuspended in denaturing buffer (100 mM Tris-HCl, 6 M guanidine-HCl, pH 8.0) and disrupted by sonication. Cell debris was removed by centrifugation (30000×g, 20 min at 4 °C). The proteins in the supernatant were refolded by dialysis in to refolding buffer (0.9 M guanidine-HCl, 100 mM Tris-HCl, 5 mM methionine, 5 mM cysteine, pH 8.0). After repeated change of dialysis buffer, the protein debris was removed by centrifugation (30000×g, 20 min at 4 °C) and the supernatants were applied to His-Trap chelating column (GE Healthcare), washed by refolding buffer and eluted with the same buffer containing 30 mM imidazole. The purified proteins were dialyzed into 1.0 v/v% acetic acid




Figure 7

Schematic model of CCL5 phases separation along with heparan sulfate on the cell surface.

The inflammatory cells secrete chemokines that are immobilized by heparan sulfate in the form of Liquid-Liquid phase separation and subsequently diffused to form a concentration gradient.

aqueous solution twice and finally into 0.1%v/v trifluoroacetic acid aqueous solution. The purity of the recombinant CCL5 was analyzed by SDS-PAGE. After lyophilization, the CCL5 proteins were dissolved in water and stored at -80°C .

For a better folding, the CCL5-EGFP and $^{44}\text{AANA}^{47}$ -CCL5-EGFP fusion proteins were expressed in *E. coli* origami2 (DE3) and induced by 0.5mM IPTG at 25°C for 12 h. The proteins were purified by the same procedure as above.

Labeling of CCL5 with Cy3

Cy3 monosuccinimidyl ester (Cy3-NHS; ATT Bioquest, USA) was mixed with CCL5 to a final concentration of 1.5 mg/mL, pH 9 adjusted with 1M NaHCO_3 . The mixture was incubated with shaking at 37°C for 1 h, and then dialyzed in a 10 kDa dialysis tube (Thermo Fisher, USA) in ddH_2O . These Cy3 stained protein were mixed with unstrained protein at 1:40-1:20 ratio when used.

Cell culture

Human Umbilical Vein Endothelial Cells (HUVEC) were cultured in Dulbecco's modified Eagle's medium (DMEM) 1× with glucose (4.5 g/L), 10% fetal bovine serum (FBS), and 1% antibiotics (penicillin/streptomycin). CHO-K1/CHO-677 cells were cultured in F12K medium containing 10% FBS and 1% antibiotics. THP-1 were cultured in RPMI1640 medium containing 10% FBS and 1% antibiotics. All cells were cultured at 37°C with 5% CO_2 in a humidified incubator.

Phase separation of CCL5 on cell surface

Cells were plated onto an eight-well Lab-Tek chambered coverglass (Thermo Fisher, USA) to around 70% confluency. Before imaging, the medium was discarded, and the cells were washed with PBS twice. Then, the protein solution diluted in the culture medium (500 nM) was added to the cells. Confocal microscopy image was captured with an inverted Leica DMI8 microscope, equipped with lasers for 489 nm, 554 nm excitation. Images were acquired using a 63× objective (oil immersion).

Z-stack for Living Cell 3-D rendering

Three-dimensional reconstruction for living cells were implemented with an inverted Leica DMI8 microscope. Images were acquired using the 63× oil immersion lens, a pinhole of 1 AU, 522 nm laser with 10% laser power, followed by setting the starting position and end position of Z-stack, 100~200 Nr. of Steps or 1 μm z-step size was selected.

Imaging of CCL5 phase separation *in vitro*

CCL5 were diluted to 4-6 mg/mL in KMEI buffer (150 mM KCl, 1 mM MgCl_2 , 1 mM Ethylenediamine tetraacetic acid (EGTA) and 10 mM Imidazole, pH 6.5). For the co-phase separation of CCL5 and heparin (GlycoNovo, China), 20 μM of CCL5 were mixed with heparin and 5% w/v PEG-8000 in the assay buffer. The mixtures were incubated at 37°C for 30 minutes then were loaded into a 96-well plate for imaging analysis. Images were captured with a Leica DMI8 confocal microscopy with a 63× objective (oil immersion) and LAS X software 3.5.

Turbidity assay

CCL5 proteins were mixed with various concentrations of heparin (0~1000 μM) and PEG-8000 (5% w/v) in the KMEI buffer. After incubation at 37°C for 30 minutes the mixture was transferred to a 96-well plate and turbidity was measured by absorption at 620 nm using a Multiskan FC microplate reader (Thermo Fisher, USA). All samples were examined in triplicates ($n = 3$).

Molecular Docking

Heparin tetrasaccharide was docked to CCL5 (PDB number: 5coy) wild type and ⁴⁴AANA⁴⁷-CCL5 (PDB number: 1u4r) mutation by ClusPro server (Desta, Porter et al. [2013](#)). The docked models were selected according to the following standards: (1) close to the critical residues, i.e., aa 44-47, (2) having the lowest energy score. The selected CCL5-heparin tetrasaccharide complex was handled by Glycan Reader & Modeler module of CHARMM-GUI (Damm, Wolfgang et al., 1997 [2013](#), Gang, Liu et al., 2013 [2013](#)) to set up the molecular dynamics simulation system and generate the input files. The energy minimization (EM) simulations of the complexes were performed with GROMACS [<https://doi.org/10.1016/j.softx.2015.06.001> [2015](#)], and based on the EM trajectory, the binding free energy between CCL5 and heparin tetrasaccharide was calculated with gmx_MMPBSA (Van Wart, Durrant et al., 2014 [2014](#)).

Diffusion of CCL5 on heparin beads and Ni-NTA beads

Heparin beads (Solarbio, China) and Ni-NTA beads (GenScript, China) 50 μ L gel were mixed with 400 ng/ μ L of CCL5-EGFP and ⁴⁴AANA⁴⁷-CCL5-EGFP fusion proteins in a total volume of 500 μ L. After incubation for 30 min in ice, the beads were dropped into Matrigel (ABWbionova, China) in 96-well plates kept on ice. Then the plates were moved to a 37 °C incubator for 12 h. Images were captured with a Zeiss AxioCam 506 color Fluorescence Microscope with a 5 $\times$, 10 $\times$ objective and analyzed with ImageJ.

Chemotaxis assay

CHO-K1, mutant CHO-677 and HUVEC cells were cultured in the lower chamber of Transwell with 8 μ m pores (Corning, USA) with a density 1×10^5 cells/well for 24 h. Cells were washed three times with PBS and then 500 nM CCL5 or the mixed solution of 500 nM CCL5 and 1mg/mL heparin (GlycoNovo, China) in culture medium were added. THP-1 cells (3×10^5) in RPMI1640 medium were placed onto upper chamber of Transwell. After incubation for 5 h in a cell incubator, the transmigrated cells (in suspension) in the lower chamber were collected and counted by cell counter and inverted microscope.

For chemotaxis assay using beads, CCL5-EGFP and ⁴⁴AANA⁴⁷-CCL5-EGFP were first mixed with the beads as described above, washed and diluted with PBS and then placed on the bottom of lower chamber. The THP-1 cells were placed in the upper chamber. Cell migration analysis was performed as described above.

Diffusion of Sec-CCL5-EGFP in cell surface

Sec-CCL5-EGFP was constructed in pCDNA3.1-EGFP vector (General Biosystems, China) and transiently expressed in CHO-K1 cells. Briefly, the cells were seeded on 6-well plated at a density of 2.5×10^5 cells/well in 2 mL medium for 24 h and then transfected using Lipo8000TM Transfection Reagent (Beyotime Biotechnology, China). After 12 h; transfected cells were detached by pancreatin (2000/mL). HUVEC cells were plated onto an eight-well Lab-Tek chambered coverglass (Thermo Fisher, USA) with a density 3×10^4 cells/well for 24 h. The transfected CHO-K1 cells (2000/mL) in 200 μ L medium were added to the eight-well coverglass coating HUVEC. After 1 h, medium was aspirated and replaced with 50% of Matrigel. The transfected CHO-K1 was co-cultured with HUVEC cells for 12 h, and images were captured with Leica DMi8 confocal microscopy with a 20 $\times$ objective. For the capture of droplets on cell surface and FRAP, the cellular membrane of HUVEC was stained with Dil (Cell membrane red fluorescent probe, Beyotime, China) for 20 min and washed three times with PBS. Images were captured with a 100 $\times$ objective (oil immersion).

Human peripheral blood cell transmigration

Blood (1 mL) was collected from three healthy volunteers in EDTA-tubes and centrifuged at 500×g (4°C for 5 min). After aspiration of plasma, the cells were treated with 10 mL of Red Blood Cell Lysis solution (Beyotime Biotechnology, China) for 10 min at 4°C and centrifuged. After removing supernatant, the cells were washed 3 times with PBS, and resuspended in 400 µL of RPMI1640 medium and counted. The cell (denoted as PBMC) suspension (100 µL) was added to the upper chamber for the chemotaxis assay as described above. All blood samples were obtained with informed consent, and the study was approved by the ethics review committee of China-Japan Friendship Hospital (2022-KY-050). All relevant ethical regulations of China-Japan Friendship Hospital and governmental regulations were followed.

Recruitment of inflammatory cells in peritoneal lavage

Eight-week-old female Balb/c mice were purchased from Charles River and kept in a pathogen-free environment with fed ad lib. The procedures for care and use of animals were approved by Beijing Municipal Science & Technology Commission, Administrative Commission of Zhongguancun Science Park (SYXK-2021-0056) and all applicable institutional and governmental regulations concerning the ethical use of animals were followed. Mice were injected intraperitoneally with 200 µL of NaCl (0.9%, lipopolysaccharide-free), 1 mg/ml heparin, 500 nM wide-type CCL5, 500nM ⁴⁴AANA⁴⁷-CCL5 or 500 nM wide-type CCL5 added by 1mg/mL heparin diluted into 200 µL of NaCl (0.9%, lipopolysaccharide-free), respectively. At 18 h post-injection mice were sacrificed by cervical dislocation, the cells in the peritoneal cavity were collected by lavage of 5 mL ice-cold PBS. The total cells collected were counted with automated cell counter (Bodibio, China).

Acknowledgements

We thank Dr. Shuibing Chen and Dr. Yongxiang Chen for help editing the manuscript.

Funding




National Key R&D Program of China 2021YFC2103900 (SZL);




National Natural Science Foundation of China 22077010 22277009 & 22261132513 (SZL)


Swedish Research Council to JPL.

Conflict of interest

The authors declare that they have no conflicts of interest with the contents of this article.







References

1. Brandner B, Rek A, Diedrichs-Möhring M, Wildner G, Kungl AJ (2009) **Engineering the glycosaminoglycan-binding affinity, kinetics and oligomerization behavior of RANTES: a tool for generating chemokine-based glycosaminoglycan antagonists** *Protein engineering, design & selection : PEDS* **22**:367–73
2. Damm Wolfgang, Frontera Antonio, Julian Jorgensen, William L. (1997) **OPLS all-atom force field for carbohydrates** *J Comput Chem* **18**:1955–1970
3. Desta IT, Porter KA, Xia B, Kozakov D, Vajda S **Performance and Its Limits in Rigid Body Protein-Protein Docking** :1071–1081
4. Douglas Dyer, Catherina Salanga, Brian Volkman (2015) **The dependence of chemokine–glycosaminoglycan interactions on chemokine oligomerization** *Glycobiology*
5. Gang Liu, Apurv Puri, Sriram Neelamegham (2013) **Glycosylation Network Analysis Toolbox: a MATLAB-based environment for systems glycobiology** *Bioinformatics (Oxford, England)*
6. Ghosh A, Mazarakos K, Zhou HX (2019) **Three archetypical classes of macromolecular regulators of protein liquid–liquid phase separation** *Proceedings of the National Academy of Sciences* **116**
7. Griffith JW, Sokol CL, Luster AD (2014) **Chemokines and chemokine receptors: positioning cells for host defense and immunity** *Annu Rev Immunol* **32**:659–702
8. Makarenkova Helen P., Beenken Andrew (2009) **Differential Interactions of FGFs with Heparan Sulfate Control Gradient Formation and Branching Morphogenesis** *Sci Signal* **2**
9. Hoogewerf AJ, Kuschert GS, Proudfoot AE, Borlat F, Clark-Lewis I, Power CA, Wells TN (1997) **Glycosaminoglycans mediate cell surface oligomerization of chemokines** *Biochemistry* **36**:13570–8
10. Hyman AA, Weber CA, Jülicher F (2014) **Liquid-Liquid Phase Separation in Biology** *Annual Review of Cell and Developmental Biology* **30**:39–58
11. Kicheva A, Pantazis P, Bollenbach T, Kalaidzidis Y, Bittig T, Jülicher F, González-Gaitán M (2007) **Kinetics of morphogen gradient formation.** *Science (New York NY)* **315**:521–5
12. Liang Wenguang G, Triandafillou Catherine G, Huang Teng-Yi, Zulueta Medel ML, Banerjee Shiladitya (2016) **Structural basis for oligomerization and glycosaminoglycan binding of CCL5 and CCL3** *Proc Natl Acad Sci U S A* **113**:5000–5005
13. Lortat-Jacob H, Grosdidier A, Imberty A (2002) **Structural diversity of heparan sulfate binding domains in chemokines** *Proc Natl Acad Sci U S A* **99**:1229–34
14. Massena S, Christoffersson G, Hjertström E, Zcharia E, Vlodavsky I, Ausmees N, Rolny C, Li JP, Phillipson M (2010) **A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils** *Blood* **116**:1924–31

15. Mulloy B (2005) **The specificity of interactions between proteins and sulfated polysaccharides** *Anais da Academia Brasileira de Ciencias* **77**:651–64
16. Nakashima KK, Vibhute MA, Spruijt E (2019) **Biomolecular Chemistry in Liquid Phase Separated Compartments** *Frontiers in molecular biosciences* **6**
17. Oshima K, King SI, McMurtry SA, Schmidt EP (2021) **Endothelial Heparan Sulfate Proteoglycans in Sepsis: The Role of the Glycocalyx** *Seminars in thrombosis and hemostasis* **47**:274–282
18. Proudfoot A, Fritchley S, Borlat F, Shaw JP, Wells T (2001) **The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity** *Journal of Biological Chemistry* **276**:10620–10626
19. Proudfoot A, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, Wells T (1996) **Extension of Recombinant Human RANTES by the Retention of the Initiating Methionine Produces a Potent Antagonist** *Journal of Biological Chemistry* **271**:2599–2603
20. Proudfoot AE, Borlat F (2000) **Purification of recombinant chemokines from E. coli. Methods in molecular biology (Clifton NJ)** **138**:75–87
21. Proudfoot AE, Handel TM, Johnson Z, Lau EK, Liwang P, Clark LI, Borlat F, Wells TN, Kosco Vilbois MH (2003) **Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines** *Proc Natl Acad Sci U S A* **100**:1885–1890
22. Proudfoot AEI, Johnson Z, Bonvin P, Handel TM (2017) **Glycosaminoglycan Interactions with Chemokines Add Complexity to a Complex System. Pharmaceuticals (Basel Switzerland)**
23. Roscic-Mrkic B, Fischer M, Leemann C, Manrique A, Gordon CJ, Moore JP, Proudfoot AE, Trkola A (2003) **RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement** *Blood* **102**:1169–77
24. Roy A, Mondal S, Kordower JH, Pahan K (2015) **Attenuation of microglial RANTES by NEMO-binding domain peptide inhibits the infiltration of CD8(+) T cells in the nigra of hemiparkinsonian monkey** *Neuroscience* **302**:36–46
25. Schier A, Needleman D (2009) **Developmental biology: Rise of the source-sink model** *Nature* **461**:480–1
26. Simon Davis DA, Parish CR (2013) **Heparan sulfate: a ubiquitous glycosaminoglycan with multiple roles in immunity** *Frontiers in immunology* **4**
27. Van Wart AT, Durrant J, Votapka L, Amaro RE (2014) **Weighted Implementation of Suboptimal Paths (WISP): An Optimized Algorithm and Tool for Dynamical Network Analysis** *Journal of Chemical Theory & Computation* **10**:511–517
28. Weber M, Hauschild R, Schwarz J, Moussion C, Sixt M (2013) **Interstitial Dendritic Cell Guidance by Haptotactic Chemokine Gradients** *Science* **339**:328–332
29. Xie M, Li JP (2019) **Heparan sulfate proteoglycan - A common receptor for diverse cytokines** *Cellular signalling* **54**:115–121

30. Xue S, Gong R, He F, Li Y, Wang Y, Tan T, Luo S (2019) **Low-complexity domain of U1-70K modulates phase separation and aggregation through distinctive basic-acidic motifs** *Science advances* **5**
31. Xue S, Zhou F, Zhao T, Zhao H, Wang X, Chen L, Li J, Luo S (2022) **Phase separation on cell surface facilitates bFGF signal transduction with heparan sulphate** *Nature communications* **13**
32. Yamamoto T, Kambayashi Y, Otsuka Y, Afouda BA, Giuraniuc C, Michiue T, Hoppler S (2022) **Positive feedback regulation of frizzled-7 expression robustly shapes a steep Wnt gradient in *Xenopus* heart development, together with sFRP1 and heparan sulfate** *Elife*
33. Ynebrten I, Barois N, Bergeland T, K  chler A, Haraldsen G (2015) **Oligomerized, filamentous surface presentation of RANTES/CCL5 on vascular endothelial cells** *Sci Rep* **5**
34. Yu SR, Burkhardt M, Nowak M, Ries J, Petrasek Z, Scholpp S, Schwille P, Brand M (2009) **Fgf8 morphogen gradient forms by a source-sink mechanism with freely diffusing molecules** *Nature* **461**:533–6
35. Zbinden A, P  rez-Berlanga M, Rossi PD, Polymenidou M (2020) **Phase Separation and Neurodegenerative Diseases: A Disturbance in the Force** *Developmental Cell* **55**:45–68

Article and author information

Xiaolin Yu

Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China

Guangfei Duan

Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China

Pengfei Pei

Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China

Long Chen

Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China

Renji Gu

Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China

Wenrui Hu

Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China

Hongli Zhang

Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China

Yan-Dong Wang

Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China

Lili Gong

Institute of Medical Science, China-Japan Friendship Hospital, Beijing, 100029, China

Lihong Liu

Institute of Medical Science, China-Japan Friendship Hospital, Beijing, 100029, China

Ting-Ting Chu

Greater Bay Biomedical InnoCenter, Shenzhen Bay Laboratory, Shenzhen, China

For correspondence: tingtingchu@szbl.ac.cn

Jin-Ping Li

Beijing Advanced Innovation Centre for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, China, Department of Medical Biochemistry and Microbiology, University of Uppsala, Uppsala, Sweden

For correspondence: jin-ping.li@imbim.uu.se

Shi-Zhong Luo

Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China

For correspondence: luosz@mail.buct.edu.cn

Copyright

© 2024, Yu et al.

This article is distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.

Editors

Reviewing Editor

Mauro Teixeira

Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

Senior Editor

Jonathan Cooper

Fred Hutchinson Cancer Research Center, Seattle, United States of America

Reviewer #1 (Public Review):

Summary:

In their manuscript, Yu et al. describe the chemotactic gradient formation for CCL5 bound to - i.e. released from - glycosaminoglycans. The authors provide evidence for phase separation as the driving mechanism behind chemotactic gradient formation. A conclusion towards a general principle behind the finding cannot be drawn since the work focuses on one chemokine only, which is particularly prone to glycan-induced oligomerisation.

Strengths:

The principle of phase separation as a driving force behind and thus as an analytical tool for investigating protein interactions with strongly charged biomolecules was originally introduced for protein-nucleic acid interactions. Yu et al. have applied this in their work for the first time for chemokine-heparan sulfate interactions. This opens a novel way to investigate chemokine-glycosaminoglycan interactions in general.

Weaknesses:

As mentioned above, one of the weaknesses of the current work is the exemplification of the phase separation principle by applying it only to CCL5-heparan sulfate interactions. CCL5 is known to form higher oligomers/aggregates in the presence of glycosaminoglycans, much more than other chemokines. It would therefore have been very interesting to see, if similar results in vitro, in situ, and in vivo could have been obtained by other chemokines of the same class (e.g. CCL2) or another class (like CXCL8).

In addition, the authors have used variously labelled CCL5 (like with the organic dye Cy3 or with EGFP) for various reasons (detection and immobilisation). In the view of this reviewer, it would have been necessary to show that all the labelled chemokines yield identical/similar molecular characteristics as the unlabelled wildtype chemokine (such as heparan sulfate binding and chemotaxis). It is well known that labelling proteins either by chemical tags or by fusion to GFPs can lead to manifestly different molecular and functional characteristics.

<https://doi.org/10.7554/eLife.93871.1.sa1>

Reviewer #2 (Public Review):

Although the study by Xiaolin Yu et al is largely limited to in vitro data, the results of this study convincingly improve our current understanding of leukocyte migration.

(1) The conclusions of the paper are mostly supported by the data although some clarification is warranted concerning the exact CCL5 forms (without or with a fluorescent label or His-tag) and amounts/concentrations that were used in the individual experiments. This is important since it is known that modification of CCL5 at the N-terminus affects the interactions of CCL5 with the GPCRs CCR1, CCR3, and CCR5 and random labeling using monosuccinimidyl esters (as done by the authors with Cy-3) is targeting lysines. Since lysines are important for the GAG-binding properties of CCL5, knowledge of the number and location of the Cy-3 labels on CCL5 is important information for the interpretation of the experimental results with the fluorescently labeled CCL5. Was the His-tag attached to the N- or C-terminus of CCL5? Indicate this for each individual experiment and consider/discuss also potential effects of the modifications on CCL5 in the results and discussion sections.

(2) In general, the authors appear to use high concentrations of CCL5 in their experiments. The reason for this is not clear. Is it because of the effects of the labels on the activity of the protein? In most biological tests (e.g. chemotaxis assays), unmodified CCL5 is active already at low nM concentrations.

(3) For the statistical analyses of the results, the authors use t-tests. Was it confirmed that data follow a normal distribution prior to using the t-test? If not a non-parametric test should be used and it may affect the conclusions of some experiments.

<https://doi.org/10.7554/eLife.93871.1.sa0>